Efficacy and safety of corpus callosotomy versus vagus nerve stimulation as long-term adjunctive therapies in children with Lennox–Gastaut syndrome

Experience of a tertiary care center

Ghalib M. Alanazi, MD, Turki F. ALOsaimi, MD, Ali H. Alwadei, MD, Ali D. Al-Otaibi, MD, Lamya A. Jad, MD, Alawi A. Al-Attas, MD.

ABSTRACT

Objectives: To compare the efficacy and safety of corpus callosotomy versus vagus nerve stimulation (VNS) as long-term adjunctive therapies in children with Lennox–Gastaut syndrome.

Methods: This retrospective study was conducted in King Fahad Medical City between 2010 and 2019. The authors identified and followed 9 patients with Lennox–Gastaut syndrome (LGS) who underwent corpus callosotomy or VNS implantation for at least 12 months; seizure frequency and major complications were monitored. Five patients with a mean age of 10.8±1.3 years had corpus callosotomy, and 4 patients with a mean age of 13.8±3.9 years were implanted with VNS stimulators.

Results: Reduction in seizure frequency was achieved in all 5 patients who underwent corpus callosotomy, with greater than 75% seizure reduction in more than 50% in one, and greater than 25% in 2 respectively. However, in those implanted with VNS, 2 (50%) patients achieved a reduction in seizure frequency of greater than 75% and 2 (50%) greater than 25%, respectively. No significant difference was observed between the 2 treatment groups. One patient who underwent corpus callosotomy suffered cerebrospinal fluid leakage, and swallowing difficulties in one patient who underwent VNS.

Conclusion: Both corpus callosotomy and VNS are safe and effective as adjunctive treatments for LGS patients.

Neurosciences 2022; Vol. 27 (2): 59-64
doi: 10.17712/nsj.2022.2.20210135

From the Department of Adult Neurology (Al-Attas), Pediatric Neurology Department (Alanazi, Al Osaimi, Alwadei, Al-Otaibi, Jad), National Neuroscience Institute, King Fahad Medical City, Riyadh, Kingdom of Saudi Arabia.

Received 24th October 2021. Accepted 11th January 2022.
Address correspondence and reprint request to: Dr. Alawi A. Al-Attas, Department of Adult Neurology, National Neuroscience Institute, King Fahad Medical City, Riyadh, Kingdom of Saudi Arabia. E-mail: alawiattas@yahoo.com
ORCID ID: https://orcid.org/0000-0003-2575-1081
Lennox–Gastaut syndrome (LGS) is a severe form of childhood-onset epilepsy that was first described by Dr. Henri Gastaut in 1966. In 1950, Dr. William G. Lennox described the electroencephalogram features of this condition. It is characterized by a triad of several types of seizures, cognitive impairment, and a distinctive awake interictal EEG pattern of diffuse slow basic rhythm interrupted by spike–wave complexes (1.5–2.5 Hz) while non-REM sleep characterized by discharges that are more generalized and more frequent, comprising polyspikes and slow waves; this condition is considered to be an epileptic encephalopathy. Lennox–Gastaut syndrome accounts for approximately 2-5% of all childhood epilepsies.

Particularly in children, the incidence is estimated at 2 per 100,000, and it is more common in males. The LGS is one of the most commonly encountered drug-resistant epileptic encephalopathies, with mortality rates ranging between 3% and 7%. Moreover, the history of infantile spasms, or West syndrome, has been associated with an unfavorable prognosis.

There are many treatment options for LGS patients, such as antiepileptic medications, ketogenic diets, VNS therapy, corpus callosotomy, and resective epilepsy surgery. Systematic review and meta-analysis showed that Cannabidiol (CBD) has an antiseizure mechanism in adults and children with drug-resistant epilepsy. Furthermore, it shows a significant reduction in drop, non-drop, and All Seizures frequency. However, it has not yet been approved by the Saudi Food and Drug Authority.

Due to the difficulty of identifying and localizing single epileptogenic lesions and the presence of multifocal characteristics, most LGS patients are ineligible for resective surgery. Palliative surgical procedure for refractory epilepsy, such as corpus callosotomy, was introduced in the 1940s by Van Wagenen and Herren. Since then, it has been widely used and indicated for different types of intractable generalized seizures. On the other hand, VNS therapy was first performed in 1988. It was approved by the US Food and Drug Administration as an adjunctive therapy for drug-resistant epilepsy in those who are not surgical candidates.

Both procedures can be used to reduce seizure frequency and severity in LGS patients. The corpus callosum is a bundled white matter fiber that connects both hemispheres to allow slow brain waves to travel back and forth between both cerebral hemispheres during slow-wave sleep (SWS). Avvenuti et al suggest that having a well-connected corpus callosum is essential for the cross-hemispheric dispersion of slow waves during sleep slow waves, non-rapid eye movement (NREM) sleep. According to the authors, this is the first time that sleep researchers have identified that non-REM sleep “slow waves” travel between brain hemispheres via so-called “anatomical highways” in the corpus callosum.

Our study evaluates the efficacy and safety of corpus callosotomy versus VNS as long-term adjunctive therapies in children with LGS in King Fahad Medical City. To our knowledge and as revealed by a search of the relevant literature, this study is a unique of its novelty in Saudi Arabia and the Middle East.

**Methods.** This retrospective study was approved by the Institutional Review Board (IRB log number 19-012) of King Fahad Medical City. In total, we studied 9 children with LGS, whose mean ages were between 10.8±1.3 and 13.7±3.9 years. They were divided into two groups and treated with either corpus callosotomy or VNS at the Epilepsy Monitoring Unit at King Fahad Medical City. All patients had pharmaco-resistant epilepsy and their main number of antiepileptic drugs (AEDs) in either groups, whether before or after surgery was almost same and the difference was not significant. An epileptic focus could not be resected in any of the patients. All the subjects underwent either corpus callosotomy or VNS between 2010 and 2019, and all received follow-up for at least 12 months. The medical records and seizure diaries of all the subjects were retrospectively reviewed for their demographic characteristics (age, gender, age of onset, seizure frequency, seizure duration before surgery, and follow-up duration), clinical characteristics (primary seizure type, brain magnetic resonance imaging [MRI] lesions, number AEDs before and after surgery, compliance with the regimen, and any change in AEDs). Complications arising from the procedures mentioned above were reviewed.

**Corpus callosotomy procedure.** All patients in this group underwent complete corpus callosotomy comprising anterior and posterior corpus callosum surgical resection.

---

**Disclosure.** Authors have no conflict of interests, and the work was not supported or funded by any drug company.
Surgical options for LGS ... Alanazi et al

Table 1 - Demographic analysis and clinical characteristics of the study subjects.

| Patient characteristics          | Corpus callosotomy | VNS | P-value |
|----------------------------------|--------------------|-----|---------|
| **Number of patients**           | 5                  | 4   |         |
| Age (years)                      | 10.8±1.3           | 13.8±3.9 | 0.15 |
| Male/female                      | 4/1                | 0/4 | 0.02   |
| Age of seizure onset (months)    | 20.6±30.6          | 18.8±20.5 | 0.68 |
| Seizure duration before surgery (years) | 8.2±3.1           | 12.0±3.6 | 0.13 |
| Follow-up duration (months)      | 15.2±3.6           | 24.5±16.5 | 0.25 |
| Mean age at surgery (years)      | 9.6±1.1            | 11.7±3.3 | 0.21 |
| Length of surgery (minutes)      | 291.4±61.6         | 113.75±12.5 | 0.002 |
| Length of hospitalization (days) | 9.6±4.4            | 7.25±3.5 | 0.41   |

**Main seizure types**
- Atonic/tonic with head drops: 5/2
- Generalized tonic seizure: 0/1
- Generalized tonic–clonic seizure: 0/1

**MRI findings**
- Atrophic change: 0/2
- Pachygyria–lissencephaly with band heterotopias: 1/0
- Normal: 4/2

**Number of antiepileptic medications**
- Before surgery: 3.4±1.1 vs 3.5±1.3, p = 0.91
- After surgery: 3.4±1.1 vs 3.0±1.1

**Change in antiepileptic medications**
- Not changed: 3 vs 3, p = 0.53
- Increased: 0 vs 0
- Decreased: 2 vs 1

Table 2 - Comparison of seizure reduction rates (all seizure types) and documented complications of patients treated with corpus callosotomy and vagal nerve stimulation.

| Seizure reduction rate | Corpus callosotomy | VNS | Comparison p-value |
|------------------------|--------------------|-----|-------------------|
| >75%                   | 2                  | 2   | 0.64              |
| >51–74%                | 1                  | 0   | 0.34              |
| ≤50%                   | 2                  | 2   | 0.83              |

**Complications**
- Cerebrospinal fluid: 1/5 vs 1/4, p = 0.72
- Swallowing difficulty: 0 vs 1
- No: 4 vs 3

VNS parameters. For the patients in this group, a VNS stimulator was implanted in the left anterior chest wall under the skin. The tool wire was wrapped inside the neck around the left vagus nerve. The VNS device was activated 1–2 weeks after implantation of the stimulator. The stimulation was started with the following parameters: an output current of 0.25 mA, a magnet current of 0.50 mA, a pulse width of 500 μs, a signal on time of 30 s, and a signal off time of 5 min. The output current and magnet current intensities were increased by 0.25 mA, as tolerated, until 2.0 mA when seizure control was insufficient, the signal off time was adjusted from 5 to 1.8 min.

Statistical analysis. As the sample size was small, the proportional differences between the 2 groups were measured by a Fisher’s exact test. The mean difference between the 2 groups was measured by a student’s t-test. The inferences were drawn at the 95% confidence interval, and a p-value of less than 0.05 was considered statistically significant.

Results. This retrospective study was approved by the Institutional Review Board (IRB log number 19-012) of King Fahad Medical City. In total, we studied 9 children with LGS, whose mean ages were between
10.8±1.3 and 13.7±3.9 years. They were divided into 2 groups and treated with either corpus callosotomy or VNS at the Epilepsy Monitoring Unit at King Fahad Medical City. All patients had pharmacoresistant epilepsy and their main number of antiepileptic drugs (AEDs) in either groups, whether before or after surgery was almost same and the difference was not significant. An epileptic focus could not be resected in any of the patients. All the subjects underwent either corpus callosotomy or VNS between 2010 and 2019, and all received follow-up for at least 12 months. The medical records and seizure diaries of all the subjects were retrospectively reviewed for their demographic characteristics (age, gender, age of onset, seizure frequency, seizure duration before surgery, and follow-up duration), clinical characteristics (primary seizure type, brain magnetic resonance imaging [MRI] lesions, number AEDs before and after surgery, compliance with the regimen, and any change in AEDs). Complications arising from the procedures mentioned above were reviewed.

**Corpus callosotomy procedure.** All patients in this group underwent complete corpus callosotomy comprising anterior and posterior corpus callosum surgical resection.

**The VNS parameters.** For the patients in this group, a VNS stimulator was implanted in the left anterior chest wall under the skin. The tool wire was wrapped inside the neck around the left vagus nerve. The VNS device was activated 1–2 weeks after implantation of the stimulator. The stimulation was started with the following parameters: an output current of 0.25 mA, a magnet current of 0.50 mA, a pulse width of 500 μs, a signal on time of 30 s, and a signal off time of 5 min. The output current and magnet current intensities were increased by 0.25 mA, as tolerated, until 2.0 mA when seizure control was insufficient, the signal off time was adjusted from 5 to 1.8 min.

**Statistical analysis.** As the sample size was small, the proportional differences between the 2 groups were measured by a Fisher’s exact test. The mean difference between the 2 groups was measured by a student’s t-test. The inferences were drawn at the 95% confidence interval, and a p-value of less than 0.05 was considered statistically significant.

**Discussion.** Both surgical procedures are effective treatment modalities in children and adolescents with LGS. However, corpus callosotomy could be an effective primary choice if atonic (drop attack) seizures are the main seizure type. On the other hand, VNS is preferred if myoclonic seizures, generalized tonic–clonic, or atypical absence seizures are the prominent seizure types. Both procedures have shown comparable efficacy. Indeed, the lower morbidity and complication rates reported with VNS implantation make it the first-line treatment. Maehara et al reported seizure cessation or a 90% greater reduction in drop attacks in 44 of 52 patients (85%) who underwent total corpus callosotomy and were followed up for at least 40 months. Both surgical treatments are safe for atonic seizures, but corpus callosotomy shows more promise in the treatment of
this highly morbid seizure type. The VNS therapy has been shown to reduce seizure rates by 50% or more in about 25% of patients and an average of approximately 20–30% in the remaining patients. A large retrospective study involving 50 LGS patients who received VNS therapy from 6 centers showed median reductions in total seizures of 42% at one month, 58.2% at 3 months, and 58% at 6 months; no significant complications were documented. You et al reported 24 patients with LGS, 14 of whom underwent corpus callosotomy, and 10 of whom received VNS implantation. The primary seizure type in all the patients was drop attack (tonic or atonic). According to the results, 64.3% of the corpus callosotomy patients exhibited a reduction in seizure frequency of more than 50%, while 70% of patients in the VNS group showed the same reduction with few tolerable transient complications. Recently, the effectiveness and responsiveness of a combined intervention, namely, VNS following corpus callosotomy, in patients with LGS was studied by Katagiri et al where he reported that 60% of the patients had a successful seizure reduction rate of 50% or more for residual seizures regardless of seizure type (except for drop attacks). Moreover, 20% of the patients were seizure-free at 12 months post-VNS. Indeed, excellent seizure outcomes for patients suffering from drop attacks were achieved after corpus callosotomy in 77.8% of patients with drop attacks. Our data revealed that corpus callosotomy and VNS were similarly effective in reducing seizures in intractable LGS patients if patients were appropriately selected as per the modalities of the administered treatments. The complication rate in our study was similar in both groups, although the corpus callosotomy was associated with more severe complications than those in the VNS group.

Our study was a nonrandomized retrospective case series involving 9 patients with Lennox–Gastaut syndrome. In our analysis, all the patients showed seizure reductions to variable extents. The primary type of seizure was head-drop in most patients in both groups. Despite the interesting results, this research has some limitations and due to the rarity of this condition, the number of patients was small, and therefore the statistical tests were less powerful. Other limitations include differences in duration of seizures before surgery and length of follow-up after treatment.

**Conclusion.** Our data revealed no significant differences in the efficacy and safety of corpus callosotomy versus VNS as a treatment for children with LGS. However, the safety profile was more favorable in the VNS group. More extensive research studies with a larger number of patients are needed to evaluate the most beneficial therapeutic procedure for patients with LGS.

**Acknowledgement.** The authors would like to thank Dr. Gehadd Al Hajaj, epilepsy fellow for his support during data collection and many thanks for Mr. Tariq Wani, for facilitating statistical analysis. The authors would like to thank also Scribendi company for English language editing.

**References**

1. Gastaut H, Tassinari CA, Roger J, Soulaway R, Jean MS, Regis H, et al. Epileptic encephalopathy in children with slow diffuse spike-waves (or petit mal variant) or Lennox syndrome. *Recenti Prog Med* 1968; 45: 117-146.
2. Lennox WG, Davis JP. Clinical correlates of the fast and the slow spike-wave electroencephalogram. *Pediatrics* 1950; 5: 626-644.
3. Markand ON, Lennox-Gastaut syndrome (childhood epileptic encephalopathy). *J Clin Neurophysiol* 2003; 20: 426-441.
4. Archer, JS, Warren AE, Jackson GD, Abbott DF. Conceptualizing Lennox–Gastaut syndrome as a secondary network epilepsy. *Front Neurol* 2014; 5: 225.
5. Camfield PR. Definition and natural history of Lennox-Gastaut syndrome. *Epilepsia* 2011; 52: 3-9.
6. Khan S and Al Badrie R. Epileptic encephalopathies: an overview. *Epilepsy Res Treat* 2012; 2012.
7. Bourgeois BF, Douglass LM, Sankar R. Lennox-Gastaut syndrome: a consensus approach to differential diagnosis. *Epilepsia* 2014; 55: 4-9.
8. Heiskala H. Community-based study of Lennox-Gastaut syndrome. *Epilepsia* 1997; 38: 526-531.
9. Trevarthan E, Murphy CC, Yeagin-Allsopp M. Prevalence and descriptive epidemiology of Lennox-Gastaut syndrome among Atlanta children. *Epilepsia* 1997; 38: 1283-1288.
10. Asadi-Pooya AA, Sharifzade M. Lennox–Gastaut syndrome in south Iran: Electro-clinical manifestations. *Seizure* 2012; 21: 760-763.
11. VanStraten AF, Ng YT. Update on the management of Lennox-Gastaut syndrome. *Pediatr Neurol* 2012; 47: 153-161.
12. Lattanzi S, Brigo F, Cagnetti C, Trinka E, Silvestrini M. Efficacy and safety of adjunctive cannabidiol in patients with Lennox–Gastaut syndrome: a systematic review and meta-analysis. *CNS drugs* 2018; 32: 905-916.
13. Wagenen VWP, Herren RY. Surgical division of commissural pathways in the corpus callosum: relation to spread of an epileptic attack. *Arch Neuropsych* 1940; 44: 740-759.
14. Asadi-Pooya AA, Sharan A, Nei M, Sperling MR. Corpus callosotomy. *Epilepsy & Behavior* 2008; 13: 271-278.
15. Penry JK, Dean JC. Prevention of intractable partial seizures by intermittent vagal stimulation in humans: preliminary results. *Epilepsia* 1990; 31: S40-S43.
16. Morris GL, Gloss D, Buchhalter J, Mack KJ, Nickels K, Harden C. Evidence-based guideline update: vagus nerve stimulation for the treatment of epilepsy: report of the Guideline Development Subcommittee of the American Academy of Neurology. *Neurology* 2013; 81: 1453-1459.
17. Lancman G, Virk M, Shao H, Mazumdar M, Greenfield JP, Weinstein S, et al. Vagus nerve stimulation vs. corpus callosotomy in the treatment of Lennox–Gastaut syndrome: a meta-analysis. Seizure 2013; 22: 3-8.

18. You SJ, Kang HC, Ko TS, Kim HD, Yum MS, Hwang YS, et al. Comparison of corpus callosotomy and vagus nerve stimulation in children with Lennox–Gastaut syndrome. Brain Dev 2008; 30: 195-199.

19. Avvenuti G, Handjaras G, Betta M, Cataldi J, Imperatori LS, Simona Lattanzi S, et al. Integrity of Corpus Callosum Is Essential for theCross-Hemispheric Propagation of Sleep Slow Waves: A High-Density EEG Study in Split-Brain Patients. J Neurosci 2020; 40: 5589-5603.

20. Cukiert A, Cukiert CM, Burattini JA, Lima AM, Forster CR, Baise C, et al. Long-term outcome after callosotomy or vagus nerve stimulation in consecutive prospective cohorts of children with Lennox–Gastaut or Lennox-like syndrome and non-specific MRI findings. Seizure 2013; 22: 396-400.

21. Maehara T, Shimizu H. Surgical outcome of corpus callosotomy in patients with drop attacks. Epilepsia 2001; 42: 67-71.

22. Rolston JD, Englot DJ, Wang DD, Garcia PA, Chang EE. Corpus callosotomy versus vagus nerve stimulation for atonic seizures and drop attacks: a systematic review. Epilepsy Behav 2015; 51: 13-17.

23. Hosain S, Nikolov B, Harden C, Li M, Fraser R, Labar D. Vagus nerve stimulation treatment for Lennox-Gastaut syndrome. J Child Neurol 2000; 15: 509-512.

24. Majoie HM, Berfelto MW, Aldenkamp AP, Evers SM, Kessels AG, Renier WO. Vagus nerve stimulation in children with therapy-resistant epilepsy diagnosed as Lennox-Gastaut syndrome: clinical results, neuropsychological effects, and cost-effectiveness. J Clin Neurophysiol 2001; 18: 419-428.

25. Frost M, Gates J, Helmers SL, Wheless JW, Levisohn P, Tardo C, et al. Vagus nerve stimulation in children with refractory seizures associated with Lennox–Gastaut syndrome. Epilepsia 2001; 42: 1148-1152.

26. Katagiri M, Iida K, Kagawa K, Hashizume A, Ishikawa N, Hanaya R, et al. Combined surgical intervention with vagus nerve stimulation following corpus callosotomy in patients with Lennox-Gastaut syndrome. Acta Neurochirurgica 2016; 158: 1005-1012.